Vennett Capital

I strongly believe that Wall Street is under appreciating the Alani acquisition. If you spend 10 minutes on social media you can quickly see the brand loyalty of Alani. Bullish on $CELH $40 over next 12 months

@TeleHInvesting Play them both 🤝

@CapitalVennett Like this play, but I love the plays that will pop even more on that approval 😏

Been loading some $LLY in front of FDA approval of Orfo. Would expect a similar pop maybe a little smaller than when $NVO got approval for Wegovy. In a good spot technically as well. Right on the 200MA on the daily Long at $900

@SixSigmaCapital @vladtenev It was approved but not specific date yet to be enacted. Been loading $HOOD and $BULL down here.

@CapitalVennett @vladtenev Wasn’t aware of that. When is that rule changing?

The team at $HOOD must have read and I see @vladtenev is doing an additional $1.5B buyback

@SixSigmaCapital @vladtenev x.com/tony_battista/…

@SixSigmaCapital @vladtenev Any thoughts on the soon to be enacted lower PDT min from $25k to $2k. Feel like no one is talking about it and could be huge for overall volume on the platform

@CarsonTalkMoney @LongGameEquity They announced the acquisition last year during their Feb earnings. Stock was trading at low 20s. Not sure where you're getting $41 a share

@LongGameEquity What do you mean? Earnings and the acquisition were different days I though

I guess the Alani deal was bad for $CELH? We officially are down 13.50% since the Alani acquisition was announced (doubling Celsius revenue ) …. This is one of the dumbest sell offs I have ever seen, I’ll continue to buy more

$CELH spent years building a brand. $COST spent 10 minutes putting “Kirkland Signature” on a 200mg caffeine can and pricing it like bottled water.

Buying some $CELH on this $COST energy drink release panic selling. Although not bullish, I think this selloff is overdone. Are people forgetting that you need a Costco card to even buy this plus what % of their total sales is even from Costco? Not warranted a 20% hit. Long $36

@labubu_trader No leverage… yet long $TQQQ?

My current view on the U.S. stock market: Geopolitics could get worse before it gets better—but I remain optimistic. Why downside risk still exists: Trump appears highly motivated to exit the war, but key uncertainties remain: the Strait is still closed, and enriched uranium destruction is unconfirmed. That leaves room for escalation scenarios—targeting power infrastructure, boots on the ground near Kharg Island, or even use of tactical nukes (e.g. B61 to bomb the underground facility) to force negotiations. As Bessent said: “50 days of higher prices for 50 years of no Iran nukes” “Sometimes you have to escalate to de-escalate.” Why I’m still optimistic: First let's check how the war impacts the markets: Oil ↑ → headline PCE ↑ → core PCE ↑ → fewer cuts / potential hikes → yields ↑ → PE multiples ↓ -> stock price ↓ So the two reasons I'm thinking it's still much better than 2022: 1. Nasdaq has already consolidated ~6 months while EPS surged → forward P/E reset near last year’s “Liberation Day” levels 2. Pre-Ukraine war PCE was ~7%; today ~2.8% → far less pressure for aggressive hikes vs 2022 So even a severe scenario likely < 2022 drawdown. And my estimates of the bear cases: Extremely bear case: QQQ ~ -10%(2022 level) Bear case: SPX ~6150, NDX ~22200 (Feb ’25 ATH zone) What's my strategy? Stay 20–25% invested (no leverage no margin). Holding $TQQQ / $MU / $SNDK. Double position at SPX 6150, and double again on either extreme downside(2022 case) or trend reversal (20EMA > 50EMA) after things settle down. Why still prefer storage names? Low PE multiple, trading ~5x ’26 EPS / ~3x ’27 EPS (per @FundaAI ).

@JPATrades Not like we werent down 2% on Friday pricing some doom for Monday

Honestly I’m stunned

@Credib1eGuy @grok what publicly traded companies would benefit from this

If this actually escalates Canada will have no choice to build Potentially setting up the pipelines and LNG stocks to go ballistic

@FurtureRichKid Fidelity the best

I am leaving $HOOD. What brokerages do y’all use? Can’t have a gambling app hold my future.

@SubuTrade Triple witching

$SPY volume today jumped to the highest since last November's bottom. Are we getting closer to capitulation? ⬇️

@orrdavid Can’t you easily fabricate high batting averages?

"Every PM on the street is judged on three things: — Number of at-bats — Hit rate against those at-bats — Sizing against that hit rate" Militia evaluates PMs this way, too. You're wasting time if you send us a track record without this crucial information. All investing firms and allocators *should* be thinking this way. But the majority do not. Many allocate based on your narrative. And so if you want to get into the professional marketing business, rather than focus on numbers and performance, you should target those allocators instead. Militia will never give you money, but they might!

@jayskywalker16 @blondesnmoney 150 x 100 shares at $10 = $150000 cash use if not using margin. Assume an average contract premium of $.67 x 150 contracts = $10,050 ($10,050/$150000)x 100 = 6.7%

@blondesnmoney @CapitalVennett How do you get a 6.75% return? I see the Dec 18 P10 trading at 0.66 x 0.70, which is a 1.5-1.6% return in 9 months. What am I missing?

I don't know what the fair value of $IREN is, but I have been selling December 10 Strike Puts on it. The use of an ATM program in the 40s is highly accretive to Tangible Book Value and I don't expect the stock to be trading below book value at the end of the year.

$WW Nice rebound from weak Friday close at $21. Shorts clearly sat on it into close. Looks like they don’t want it over $25 today. Think we can see $27-$30 range in the coming weeks though. Still so cheap Don’t forget $LLY Orfo approval next month should be a good catalyst 🍻

$WW happy with Q4 numbers and encouraged by strong clinical guide. Remember that they will be guiding very conservatively as they have just gotten out of bankruptcy.

$WW. “End of Period Clinical Subscriber momentum accelerated in Q1 2026 despite lapping significant prior year growth in Q1 2025 driven by the Company’s former compounded semaglutide offering.”